MONMOUTH JUNCTION, N.J., March31, 2020 /PRNewswire/ --CytoSorbents, Inc.(NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world,announced that its CytoSorb cytokine adsorber has been approved to be marketed and sold in Mexico by the country's health authority, COFEPRIS. COFEPRIS, or the Federal Committee for Protection from Sanitary Risks (Comisin Federal para la Proteccin contra Riesgos Sanitarios) is responsible for regulating the importation of medical devices into the country.
As previously announced, Fresenius Medical Care (FMC) maintains the exclusive rights to distribute CytoSorb for acute care and other hospitalapplications in Mexico. These include indications where cytokines (e.g. sepsis, endocarditis, acute respiratory distress syndrome), bilirubin (e.g. liver disease), or myoglobin (e.g. trauma) are elevated. With this approval, commercial promotional activities and sales of CytoSorb may now officially commence in Mexico.
Mr. Ignacio Castan, President of Fresenius Medical Care Mexico commented, "Each year in Mexico, hyperinflammatory conditions such as septic shock, severe lung injury, trauma, and acute flares of chronic liver disease lead to a staggering human and economic toll due to a lack of effective therapies. We are very excited to now bring CytoSorb to doctors and patients throughout Mexico that are dealing with these conditions on a daily basis, particularly now as the number of hospital admissions due to COVID-19 pneumonia are expected to rise dramatically. The FMC Mexico team has been preparing the market and we are ready to go. We hope to have a positive impact on patient care in Mexico with CytoSorb."
Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents, stated, "We are pleased to have successfully achieved the registration of CytoSorb in Mexico and plan to fulfill initial orders from FMC this quarter. Given the COVID-19 pandemic, the approval is timely, providing physicians in Mexico access to an additional tool to fight cytokine storm and inflammation, common themes in those infected with COVID-19. We are excited to expand our existing relationship with Fresenius to now include Mexico. Through the acquisition of NxStage and Xenios, Fresenius has increased its intensive care unit footprint in North America to serve those critically-ill patients that require continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO). Both modalities are commonly used with CytoSorb. We look forward to supporting FMC in a successful market launch of CytoSorb in Mexico."
Mr. Chris Cramer, Vice President of Business Development at CytoSorbents stated, "This approval takes on an even greater importance now, as the number of serious COVID-19 infections in Mexico continues to rise. We are pleased that FMC Mexico can now promote and make CytoSorb available to physicians throughout the country for a wide variety of acute care and other hospital-based conditions. Having worked closely together in Europe for the past several years, we plan to leverage that extensive experience to help FMC's outstanding sales organization in Mexico to rapidly bring CytoSorb to the market."
Mexico is home to over 129 million people and is the second-largest medical device market in Latin America after Brazil and the 18th largest economic market in the world. Throughout the country, there is an increasing burden of illness and rising healthcare costs associated with deadly inflammatory conditions such as sepsis. Additionally, there is a growing demand for CRRT treatments for acute kidney injury (AKI) and cytokine removal in intensive care unit patients. In particular, there is a significant unmet need in patients suffering from infection and septic shock, systemic inflammation, Acute Respiratory Distress Syndrome (ARDS), liver failure, burn injury, and trauma. Healthcare in Mexico varies from the most basic primary health care, offered free by the state, to highly specialized, high-tech health services available in both the public and private sectors. According to OECD (Organization for Economic Co-operation and Development) Health Statistics, healthcare expenditure in 2018 as a percentage of GDP was 5.5% for Mexico.
Mexico has reported approximately 1,100 COVID-19 infections, with 28 deaths to date. These numbers are expected to increase exponentially in the coming weeks as the coronavirus pandemic spreads across North America. As a precautionary measure due to the anticipated rise of cases, Mexico's Deputy Health Minister, Hugo Lopez-Gatell, has urged all residents to stay at home for a month to slow down the spread of the coronavirus.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporationis a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorbis approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb has been used in more than 80,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $29 millionfrom DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM),the U.S. Army, U.S. Special Operations Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC) and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL, HemoDefend, VetResQ, K+ontrol, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at http://www.cytosorbents.com and http://www.cytosorb.com or follow us on Facebookand Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC onMarch 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Contact: Amy Vogel Investor Relations (732) 398-5394 avogel@cytosorbents.com
Investor Relations Contact: Jeremy Feffer LifeSci Advisors 917-749-1494 jeremy@lifesciadvisors.com
Public Relations Contact: Eric Kim Rubenstein Public Relations 212-805-3052 ekim@rubensteinpr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorb-receives-marketing-approval-in-mexico-with-commercialization-to-commence-with-partner-fresenius-medical-care-301032435.html
SOURCE CytoSorbents Corporation
Here is the original post:
CytoSorb Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care - BioSpace
- Home - MedStar Heart & Vascular Institute - April 16th, 2018 [April 16th, 2018]
- Guidelines for Standards in Cardiac Surgery - April 16th, 2018 [April 16th, 2018]
- Cardiac Surgery - University of Ottawa Heart Institute - June 16th, 2018 [June 16th, 2018]
- Cardiac Surgery | UNC Medical Center, Hospitals Chapel ... - June 18th, 2018 [June 18th, 2018]
- Heart Surgery | Seattle Childrens Hospital - June 18th, 2018 [June 18th, 2018]
- Pediatric Cardiac Surgery | CHKD | Norfolk, VA - June 18th, 2018 [June 18th, 2018]
- Cardiac Surgery | McLaren Port Huron - July 4th, 2018 [July 4th, 2018]
- CardioVascular Thoracic Institute (CVTI) | The most ... - July 23rd, 2018 [July 23rd, 2018]
- Top Cardiac Surgery COST in India| Benefit - IndianHealthGuru - July 27th, 2018 [July 27th, 2018]
- Cardiac Surgery - Atrial Septal Defect - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery | Stony Brook Medicine - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery in the Adult Fifth Edition: Lawrence H. Cohn ... - August 6th, 2018 [August 6th, 2018]
- Pioneers of Cardiac Surgery: 9780826515940: Medicine & Health ... - August 6th, 2018 [August 6th, 2018]
- Cardiovascular Surgery Department | Cleveland Clinic - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery - Massachusetts General Hospital, Boston, MA - September 19th, 2018 [September 19th, 2018]
- Cardiac Surgery | Surgery | UC Cincinnati College of ... - September 25th, 2018 [September 25th, 2018]
- Cardiothoracic surgery - Wikipedia - September 25th, 2018 [September 25th, 2018]
- Cardiac Surgery | NorthShore - September 25th, 2018 [September 25th, 2018]
- Open Heart Surgery - Cardiac Surgery - University of ... - September 25th, 2018 [September 25th, 2018]
- Heart Surgery | Cleveland Clinic - September 25th, 2018 [September 25th, 2018]
- Cardiac Surgery - Ventricular Assist Devices (VAD) - October 4th, 2018 [October 4th, 2018]
- VCSQI | Virginia Cardiac Services Quality Initiative ... - October 12th, 2018 [October 12th, 2018]
- Cardiac Surgery | Boston Medical Center - October 15th, 2018 [October 15th, 2018]
- Cardiac Surgery | WVU Heart and Vascular Institute - November 10th, 2018 [November 10th, 2018]
- Cardiac Surgery - Heart Valve, Bypass | GW Hospital - November 13th, 2018 [November 13th, 2018]
- Cardiac Surgery - Department of Surgery - University of ... - November 29th, 2018 [November 29th, 2018]
- Cardiac Surgery - Jersey Shore University Medical Center - December 7th, 2018 [December 7th, 2018]
- Blunt Cardiac Injury - The American Association for the ... - December 20th, 2018 [December 20th, 2018]
- Minimally invasive cardiac surgery - Wikipedia - December 20th, 2018 [December 20th, 2018]
- Heart Surgery | Private cardiac specialists in London ... - December 20th, 2018 [December 20th, 2018]
- Cardiac Surgery - Waterbury Hospital - December 20th, 2018 [December 20th, 2018]
- Cardiac surgery - Wikipedia - December 25th, 2018 [December 25th, 2018]
- Heart Surgery | Memorial Healthcare System - December 31st, 2018 [December 31st, 2018]
- A Step-By-Step Look at Open Heart Bypass Surgery - December 31st, 2018 [December 31st, 2018]
- Cardiac Surgery - Erlanger - December 31st, 2018 [December 31st, 2018]
- Inova Cardiac and Thoracic Surgery | Northern VA & DC - Inova - March 6th, 2019 [March 6th, 2019]
- Cardiac Surgery | Heart and Vascular Center | Dartmouth ... - March 13th, 2019 [March 13th, 2019]
- Cardiovascular Medicine and Cardiac Surgery - April 1st, 2019 [April 1st, 2019]
- Minimally invasive heart surgery - Mayo Clinic - April 3rd, 2019 [April 3rd, 2019]
- Home > Cardiac Surgery | Surgery | Yale School of Medicine - April 16th, 2019 [April 16th, 2019]
- Heart and Vascular Care Services - UR Medicine, University ... - April 18th, 2019 [April 18th, 2019]
- Welcome! | LHSC - April 20th, 2019 [April 20th, 2019]
- Cardiac Surgery | Department of Surgery | The University ... - April 20th, 2019 [April 20th, 2019]
- Coronary bypass surgery - Mayo Clinic - April 23rd, 2019 [April 23rd, 2019]
- Cardiovascular Surgery - Overview - Mayo Clinic - April 23rd, 2019 [April 23rd, 2019]
- Cardiac Surgery | McLaren Health Care - April 23rd, 2019 [April 23rd, 2019]
- Volunteer opens heart to his faith after healing cardiac ... - April 23rd, 2019 [April 23rd, 2019]
- Heart Surgery - UChicago Medicine - April 27th, 2019 [April 27th, 2019]
- Heart Surgery | UM St. Joseph Medical Center - May 13th, 2019 [May 13th, 2019]
- Cardiac Surgery - Billings Clinic - May 13th, 2019 [May 13th, 2019]
- Cardiology and Cardiac Surgery - Chicago Cardiologists and ... - May 23rd, 2019 [May 23rd, 2019]
- Cardiac Surgery | Michigan Medicine | University of Michigan - September 11th, 2019 [September 11th, 2019]
- Guidelines for Perioperative Care in Cardiac Surgery ... - September 11th, 2019 [September 11th, 2019]
- Cannula Market To Flourish And Reach USD 433 Million By 2025 - ZMR News Network - October 4th, 2019 [October 4th, 2019]
- Heart Health: Dr Panda says one should never give up on a patient - Republic World - October 4th, 2019 [October 4th, 2019]
- Minimally Invasive Surgery Market 2024 By Manufacturers, Investment Feasibility, Cost Structure And Swot Analysis - The Washington Observer - October 4th, 2019 [October 4th, 2019]
- Michael Schumacher health latest: What is stem cell therapy and how will it help Schumi? - Express.co.uk - October 4th, 2019 [October 4th, 2019]
- Cooperative insurance: Novel financing model aims to deliver healthcare to the middle-class segment - The Hindu BusinessLine - October 4th, 2019 [October 4th, 2019]
- Optimism Linked to Lower Risk of Cardiovascular Events and Death - Cath Lab Digest - October 4th, 2019 [October 4th, 2019]
- Global Cardiac Surgery Devices Market 2019 Innovative Trends and Insights Research upto 2024 - Markets Gazette - October 4th, 2019 [October 4th, 2019]
- Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist - Diagnostic and Interventional Cardiology - October 4th, 2019 [October 4th, 2019]
- Economics of Cochlear Implant Utilization : The Hearing Journal - LWW Journals - October 4th, 2019 [October 4th, 2019]
- How to Keep the Weight Off After Bariatric Surgery - Health Essentials from Cleveland Clinic - October 4th, 2019 [October 4th, 2019]
- Heart Lung Machine Market to Upsurge at 6.13% CAGR by 2023, Owing to Increasing Demand From the Healthcare Sector: Radiant Insights, Inc. - PRNewswire - October 4th, 2019 [October 4th, 2019]
- Annadale toddler born with rare condition is fighting for her life - SILive.com - October 4th, 2019 [October 4th, 2019]
- Ocala Health earns distinction, ranks among top within HCA open heart programs - Ocala News - October 4th, 2019 [October 4th, 2019]
- External Validation Of The Surgical Mortality Probability Model (S-MPM | TCRM - Dove Medical Press - October 4th, 2019 [October 4th, 2019]
- CytoSorb Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac... - October 4th, 2019 [October 4th, 2019]
- Transcatheter Tricuspid Fix Bests Meds Alone in Early Results - Medscape - October 15th, 2019 [October 15th, 2019]
- Senior Lecturer/Associate Professor in Medical Statistics job with UNIVERSITY OF BRISTOL | 183393 - Times Higher Education (THE) - October 15th, 2019 [October 15th, 2019]
- Complicated surgery at NICVD saves life of nine-year-old boy - The News International - October 15th, 2019 [October 15th, 2019]
- Angion Announces Several Strategic Additions to its Management Team to Support the Future Development and Commercialization of ANG-3777 - Yahoo... - October 15th, 2019 [October 15th, 2019]
- 'Sky is the limit' for heart treatment without invasive surgery - Ottawa Citizen - October 15th, 2019 [October 15th, 2019]
- Executive Profile: Dr. David Anschel - Long Island Business News - October 15th, 2019 [October 15th, 2019]
- Heart surgeon and author reveals how he once set fire to patient - The Guardian - October 15th, 2019 [October 15th, 2019]
- Demolition paves way for heart, vascular center - Midland Daily News - October 15th, 2019 [October 15th, 2019]
- The basics of research | TNS - The News on Sunday - October 15th, 2019 [October 15th, 2019]
- Senior Lecturer/Associate Professor in Medical Statistics job with UNIVERSITY OF BRISTOL | 183345 - Times Higher Education (THE) - October 15th, 2019 [October 15th, 2019]
- Sparks, Accusations Fly Over Conduct of EXCEL Trial - Medscape - October 15th, 2019 [October 15th, 2019]
- More Heart Valve Patients May Choose Minimally Invasive Procedure - Newswise - October 15th, 2019 [October 15th, 2019]